There are specific treatment options patients may qualify for depending on the cytogenetic or molecular abnormality detected.
Lisa Holle, PharmD, BCOP, FHOPA, FISOPP
Advertisement
Articles by Lisa Holle, PharmD, BCOP, FHOPA, FISOPP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Halfway There Is Nowhere
2
ADA 2026: Key Pharmacotherapy Advances in Type 1 and Type 2 Diabetes
3
Metformin Cuts Long COVID Risk by 50%, New Trial Confirms
4
Combined Food Policies, Including Labeling and Advertising Bans, Plausibly Reduce Childhood Obesity
5